Generic IOCETAMIC ACID INN entry, drug patent expiration information and freedom to operate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt	CHOLEBRINE	iocetamic acid	TABLET;ORAL	017129-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Iocetamic acid, a radiocontrast agent, demonstrates a mature market characterized by stable demand and limited innovation. Its financial trajectory is primarily influenced by established manufacturing costs, existing patent expirations, and its position within the broader diagnostic imaging sector. The agent's utility in specific diagnostic procedures, particularly cholecystography, anchors its continued use, though its market share is subject to competition from newer imaging modalities and contrast agents.

What is the current market size and projected growth for iocetamic acid?

The global market for iocetamic acid is an established segment within the broader contrast media market. Precise, up-to-the-minute market size figures are proprietary and often embedded within larger market research reports. However, industry analysis indicates a stable, albeit low single-digit, annual growth rate for older contrast agents like iocetamic acid. This growth is driven by an aging global population, increasing incidence of diagnostic imaging procedures, and its established efficacy in specific applications such as oral cholecystography and urography, which remain relevant in certain clinical pathways.

The contrast media market as a whole is projected to grow, with sources like Grand View Research forecasting a compound annual growth rate (CAGR) in the range of 6% to 8% for the period leading up to 2030 [1]. However, this overall growth is disproportionately driven by newer, higher-margin agents, particularly iodinated and gadolinium-based contrast agents used in CT and MRI scans. Iocetamic acid’s contribution to this growth is marginal, reflecting its established position and lack of significant patent-driven expansion.

Key factors contributing to the current market include:

Established Clinical Use: Iocetamic acid has a long history of use, making it a familiar and trusted agent for specific diagnostic procedures.
Cost-Effectiveness: Compared to some newer contrast agents, iocetamic acid can offer a more economical option, which is a consideration in healthcare systems focused on cost containment.
Specificity in Applications: While not a universal contrast agent, it remains a preferred choice for certain examinations where its pharmacokinetic profile is advantageous.

Conversely, factors limiting its growth include:

Competition from Advanced Imaging: The rise of MRI and advanced CT techniques, which utilize different classes of contrast agents, has reduced the reliance on agents like iocetamic acid for some diagnostic needs.
Availability of Alternative Agents: Newer oral and injectable contrast agents with improved safety profiles or broader applications have emerged.
Patent Landscape: Original patents for iocetamic acid have long expired, leading to generic competition and price erosion, which limits revenue growth potential for any single manufacturer.

What is the patent landscape surrounding iocetamic acid?

The original patents for iocetamic acid, developed in the mid-20th century, have long expired. This means that the core compound itself is off-patent, allowing for generic manufacturing. The primary patent for iocetamic acid was filed in the late 1950s and early 1960s, with its efficacy and synthesis routes becoming public knowledge shortly thereafter.

The absence of active composition-of-matter patents significantly impacts the competitive landscape. It enables multiple pharmaceutical manufacturers to produce and market generic versions of iocetamic acid. This typically results in:

Increased Competition: A larger number of manufacturers enter the market, driving down prices through competitive bidding and supply.
Price Erosion: The profit margins for iocetamic acid are considerably lower than for patented, novel contrast agents.
Focus on Manufacturing Efficiency: Companies that produce iocetamic acid tend to focus on optimizing their manufacturing processes and supply chains to maintain profitability in a price-sensitive market.

While the core compound is off-patent, there is a possibility of secondary patents related to:

New Formulations: Development of novel drug delivery systems, such as improved oral formulations, sustained-release versions, or enhanced solubility preparations, could be patentable. However, significant innovation in this area for an established agent like iocetamic acid is less likely compared to newer drugs.
New Therapeutic or Diagnostic Uses: Discovery and patenting of novel diagnostic or therapeutic applications for iocetamic acid, beyond its traditional uses, could extend its commercial life. This is also a less probable scenario given its well-understood pharmacology.
Manufacturing Processes: Patents might exist for specific, novel, or more efficient methods of synthesizing iocetamic acid. However, existing methods are well-established, making significant patentable improvements rare.

The patent expiration dates for iocetamic acid are a matter of historical record, with the key intellectual property expiring decades ago. Consequently, the current market is dominated by generic manufacturers. This contrasts sharply with the market for newly approved contrast agents, which are protected by extensive patent portfolios and often command premium pricing.

Who are the key manufacturers and suppliers of iocetamic acid?

The manufacturing and supply of iocetamic acid are distributed across several pharmaceutical companies, primarily those with a focus on generic drugs and established radiopharmaceuticals. Due to the off-patent nature of the compound, there isn't a single dominant innovator. Instead, the market comprises a mix of global and regional players.

Key players include:

Sanochemia Pharmazeutika AG: A European pharmaceutical company that has historically been a significant producer of contrast media, including iocetamic acid. They focus on developing and manufacturing active pharmaceutical ingredients (APIs) and finished dosage forms.
Bracco Imaging S.p.A.: While a major player in the broader contrast media market with many proprietary products, Bracco may also offer generic contrast agents as part of their portfolio, or have historically been involved in its supply chain.
Other Generic Manufacturers: Numerous smaller and regional pharmaceutical companies globally engage in the production of generic iocetamic acid. These companies often compete on price and supply chain reliability. Examples could include companies based in India and China, which are major hubs for generic API production.
API Suppliers: Beyond finished product manufacturers, there are companies specializing in the production of the active pharmaceutical ingredient (API) for iocetamic acid. These APIs are then sold to formulators.

The supply chain for iocetamic acid is characterized by:

Global Sourcing: Raw materials and intermediates for synthesis are often sourced globally.
API Manufacturing: Production of the iocetamic acid API may occur in specialized chemical manufacturing facilities.
Formulation and Packaging: The API is then formulated into the final dosage form (typically oral tablets) and packaged by pharmaceutical companies.
Distribution: Finished products are distributed through pharmaceutical wholesalers and directly to hospitals and clinics.

The competitive dynamics among these manufacturers are driven by:

Cost of Production: Efficiency in synthesis and manufacturing is crucial for profitability.
Regulatory Compliance: Adherence to Good Manufacturing Practices (GMP) and other regulatory standards is essential for market access.
Supply Chain Management: Ensuring a consistent and reliable supply to meet demand is a key differentiator.
Pricing: As a generic product, pricing is highly competitive.

What are the primary regulatory considerations and approval pathways for iocetamic acid?

Iocetamic acid, as a pharmaceutical product, is subject to stringent regulatory oversight in major markets. The approval pathways and ongoing compliance requirements are managed by national and regional health authorities.

Key Regulatory Authorities and Their Requirements:

United States (U.S. Food and Drug Administration - FDA):
- Approval Pathway: For generic versions, the Abbreviated New Drug Application (ANDA) pathway is used. An ANDA requires demonstrating bioequivalence to the Reference Listed Drug (RLD), proving that the generic product performs the same as the branded product.
- Manufacturing Standards: Compliance with current Good Manufacturing Practices (cGMP) is mandatory. Facilities are subject to FDA inspections.
- Labeling: Labeling must be consistent with the RLD's approved labeling, with certain permissible differences.
- Post-Market Surveillance: Manufacturers are responsible for reporting adverse events.
European Union (European Medicines Agency - EMA):
- Approval Pathway: A Marketing Authorisation Application (MAA) is required. For generics, this can be submitted through the centralized, decentralized, or mutual recognition procedures, typically relying on a dossier demonstrating quality, safety, and efficacy (bioequivalence).
- Manufacturing Standards: Compliance with EU GMP guidelines is essential. Inspections are conducted by national competent authorities.
- Labeling: Prescribing information and patient information leaflets must adhere to EU standards.
Other Jurisdictions: Similar regulatory frameworks exist in Canada (Health Canada), Japan (Pharmaceuticals and Medical Devices Agency - PMDA), and other developed markets. Developing countries often have their own regulatory bodies, which may align with or adapt international standards.

Specific Considerations for Iocetamic Acid:

Radiopharmaceutical Regulations: While iocetamic acid itself is not radioactive, its use as a contrast agent places it within the broader category of diagnostic agents. Regulatory bodies often have specific guidelines or classifications for such products.
Quality Control: Stringent quality control measures are required throughout the manufacturing process to ensure purity, potency, and stability of the drug product. This includes testing for impurities, degradation products, and dissolution profiles.
Drug Master Files (DMFs): API manufacturers often file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and controls for the API. Drug product manufacturers then reference these DMFs in their own applications.
Pharmacopeial Standards: Iocetamic acid must comply with specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.).

The regulatory environment for generic drugs is mature and well-defined. The primary challenge for manufacturers lies in navigating the specific requirements of each target market, maintaining high manufacturing standards, and ensuring timely renewal of approvals.

What is the financial trajectory and profitability outlook for iocetamic acid manufacturers?

The financial trajectory for manufacturers of iocetamic acid is characterized by stability in revenue but limited growth potential due to its generic status and mature market. Profitability is largely dependent on operational efficiency and economies of scale.

Revenue Drivers:

Volume-Based Sales: Revenue is primarily driven by the volume of iocetamic acid sold. The demand is relatively inelastic in its established applications, meaning that changes in price have a less significant impact on overall demand.
Established Market Niches: Its continued use in specific diagnostic procedures, particularly in regions with established healthcare infrastructure and cost-conscious systems, provides a consistent, albeit modest, revenue stream.
Global Reach: Manufacturers who can effectively distribute iocetamic acid across multiple geographic markets can achieve higher overall sales volumes.

Profitability Factors:

Low Profit Margins: Due to the absence of patent protection and intense generic competition, profit margins for iocetamic acid are relatively low. Manufacturers cannot command premium pricing.
Cost of Goods Sold (COGS): Profitability is heavily influenced by the cost of raw materials, manufacturing expenses, and quality control. Efficient supply chain management and optimized production processes are critical.
Economies of Scale: Larger manufacturers with higher production volumes can spread fixed costs over more units, leading to lower per-unit production costs and potentially higher profit margins.
Manufacturing Efficiency: Investments in modern, efficient manufacturing facilities and processes can significantly reduce COGS and improve profitability.
Regulatory Compliance Costs: Maintaining compliance with cGMP and other regulatory standards incurs ongoing costs, which must be factored into pricing and profitability calculations.

Financial Trajectory Outlook:

Stable but Stagnant Revenue: The revenue stream from iocetamic acid is expected to remain stable over the medium term. Significant growth is unlikely unless new, patentable applications are discovered or a major competitor exits the market.
Focus on Margin Optimization: Manufacturers will continue to focus on optimizing their cost structures to maintain or improve profitability. This includes seeking out cost-effective raw material suppliers and improving manufacturing yields.
Strategic Importance: For many generic manufacturers, iocetamic acid may represent a small but stable part of a broader portfolio of generic pharmaceuticals. Its strategic importance might lie in its contribution to market share in the contrast media segment or its ability to utilize existing manufacturing infrastructure.
Limited Investment for Innovation: Due to low margins and patent expiration, there is limited incentive for significant R&D investment in novel formulations or delivery systems for iocetamic acid. Investment is more likely to be directed towards process improvements.
Acquisition Potential: Companies with strong manufacturing capabilities and established distribution networks for generic contrast agents might be acquisition targets for larger pharmaceutical firms looking to expand their generic portfolios, though the financial attractiveness of iocetamic acid alone would be modest.

In summary, the financial outlook for iocetamic acid manufacturers is one of steady, predictable revenue generation with a focus on cost control rather than expansion. Profitability is a function of operational excellence rather than market growth.

What are the emerging trends and future outlook for iocetamic acid in diagnostic imaging?

The future outlook for iocetamic acid in diagnostic imaging is one of continued, albeit limited, relevance. Emerging trends in medical imaging and contrast media favor more advanced agents and technologies, which will likely constrain iocetamic acid's market share.

Key Emerging Trends Impacting Iocetamic Acid:

Shift Towards Advanced Imaging Modalities: The increasing adoption of MRI and advanced multi-detector CT (MDCT) scanners is driving demand for their specific contrast agents (e.g., gadolinium-based agents for MRI, iodinated contrast agents with improved viscosities and safety profiles for CT). These modalities offer higher resolution, better soft-tissue contrast, and functional imaging capabilities that iocetamic acid does not address.
Development of Novel Contrast Agents: Pharmaceutical companies are continuously investing in the research and development of new contrast agents with improved properties, such as:
- Enhanced Safety Profiles: Agents with lower nephrotoxicity, reduced allergenic potential, and better tolerability.
- Targeted Agents: Contrast agents designed to accumulate in specific tissues or bind to particular biomarkers for more precise diagnosis (e.g., for cancer detection).
- Dual-Modality Agents: Agents that can be used in multiple imaging techniques, increasing versatility.
Personalized Medicine and Biomarkers: The trend towards personalized medicine involves using imaging agents that can detect specific molecular targets or physiological states, a level of specificity not inherent to iocetamic acid.
Artificial Intelligence (AI) in Imaging: AI is being used to enhance image quality, improve diagnostic accuracy, and potentially reduce the need for certain contrast agents by extracting more information from native images.
Cost-Effectiveness Pressures: While iocetamic acid is relatively inexpensive, overall healthcare cost containment may also lead to increased scrutiny of all diagnostic procedures, potentially favoring more efficient diagnostic pathways that might reduce the use of older agents.
Environmental Considerations: Concerns about the environmental impact of contrast agents, particularly their persistence in wastewater, are leading to research into more biodegradable alternatives.

Future Outlook for Iocetamic Acid:

Continued Use in Niche Applications: Iocetamic acid will likely persist in its traditional, well-established roles, particularly oral cholecystography and certain types of urography, where it remains a cost-effective and clinically validated option, especially in resource-limited settings or for specific patient populations where newer agents are contraindicated or less suitable.
Declining Market Share: Its overall market share within the broad contrast media market is expected to gradually decline as newer imaging technologies and agents gain wider adoption.
Stable Demand in Specific Geographies: Demand may remain more stable in regions with slower adoption rates of advanced imaging technologies or where healthcare budgets prioritize cost over cutting-edge diagnostics.
Generic Competition Dominance: The market will continue to be dominated by generic manufacturers, leading to sustained price pressure and low profit margins for the product.
Limited R&D Focus: There is unlikely to be significant new investment in R&D for iocetamic acid, as innovation efforts are concentrated on novel, patent-protected agents.

The future trajectory of iocetamic acid is characterized by its role as a legacy product within a rapidly evolving diagnostic imaging landscape. Its continued presence will be defined by its specific clinical utility and cost-effectiveness in a subset of diagnostic procedures.

Key Takeaways

Iocetamic acid operates within a mature, low-growth market segment of the broader contrast media industry.
Original patents have long expired, leading to a competitive generic market with significant price pressure and thin profit margins.
Key manufacturers are primarily generic pharmaceutical companies focused on operational efficiency and economies of scale.
Regulatory approval pathways are well-established for generic versions, focusing on bioequivalence and cGMP compliance.
The financial trajectory is characterized by stable, volume-driven revenue with limited potential for significant growth or margin expansion.
Emerging trends in advanced imaging modalities, novel contrast agents, and personalized medicine are expected to gradually reduce iocetamic acid's market share, though it will likely retain relevance in specific niche applications.

Frequently Asked Questions

Will new patents for iocetamic acid formulations be filed in the near future? While theoretically possible, the likelihood of significant, patentable innovations for novel formulations of iocetamic acid is low given its established nature and the availability of newer contrast agents. Investment in such R&D is generally not prioritized for older, off-patent drugs.
What are the primary contraindications for iocetamic acid use? Major contraindications include hypersensitivity to iocetamic acid or its components, severe hepatic or renal impairment, and conditions that may delay gastrointestinal transit, such as intestinal obstruction or perforation.
How does iocetamic acid compare in cost to newer oral contrast agents? Iocetamic acid is generally considered a cost-effective option compared to many newer oral contrast agents, particularly those designed for specific applications like MRI or advanced CT imaging. Its cost is a significant factor in its continued use.
What is the expected lifespan of iocetamic acid in the diagnostic imaging market? Given its established clinical utility in specific procedures, iocetamic acid is expected to remain on the market for the foreseeable future. However, its market share will likely continue to erode as advanced imaging techniques and agents become more prevalent.
Are there any environmental concerns associated with the use and disposal of iocetamic acid? Like many iodinated contrast agents, iocetamic acid can persist in the environment if not properly managed post-excretion. Pharmaceutical waste management and wastewater treatment are considerations for its disposal, though research into biodegradability is ongoing for the broader class of contrast agents.

Citations

[1] Grand View Research. (2023). Contrast Media Market Size, Share & Trends Analysis Report By Type (X-ray/CT, MRI, Ultrasound, Contrast Enhanced Mammography), By Application (Diagnostic, Interventional), By Purity, By Region, And Segment Forecasts, 2024 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/contrast-media-market

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	22
DailyMed Link:	iocetamic acid at DailyMed

Iocetamic acid - Generic Drug Details

What are the generic drug sources for iocetamic acid and what is the scope of freedom to operate?

Summary for iocetamic acid

Anatomical Therapeutic Chemical (ATC) Classes for iocetamic acid

US Patents and Regulatory Information for iocetamic acid

Iocetamic Acid: Market Dynamics and Financial Trajectory